5. Haase A. Localization of unaffected spins in NMR imaging and spectroscopy (LOCUS spectroscopy). Magn Reson Med 1986; 3(6): 963-969. 6. Odaka K, Aoki I, Moriya J, Tateno K, Tadokoro H, Kershaw J, et al. In Vivo Tracking of Transplanted Mononuclear Cells Using Manganese-Enhanced Magnetic Resonance Imaging (MEMRI). Plos One 2011; 6(10). 7. Perez PD, Hall G, Kimura T, Ren Y, Bailey RM, Lewis J, et al. In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures. Mol Neurodegener 2013; 8: 9. 8. Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, et al. Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. EMBO J 2007; 26(24): 5143-5152. 9. Nagai T, Takata N, Shinohara Y, Hirase H. Adaptive changes of extracellular amino acid concentrations in mouse dorsal striatum by 4-AP-induced cortical seizures. Neuroscience 2015; 295: 229-236. 10. Maekawa M, Yamada K, Toyoshima M, Ohnishi T, Iwayama Y, Shimamoto C, et al. Utility of Scalp Hair Follicles as a Novel Source of Biomarker Genes for Psychiatric Illnesses. Biol Psychiatry 2015; 78(2): 116-125. 11. Matsushita T, Amagai Y, Soga T, K, Obinata M, Hashimoto S. A novel oligodendrocyte cell line OLP6 shows the successive stages of oligodendrocyte development: late progenitor, immature and mature stages. Neuroscience 2005;
136(1): 115-121. 12. Sekiguchi M, Sakakibara K, Fujii G. Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med 1978; 48(1): 61-68. 13. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18(11): 1427-1431. 14. Bossert JM, Stern AL, Theberge FR, Marchant NJ, Wang HL, Morales M, et al. Role of projections from ventral medial prefrontal cortex to nucleus accumbens shell in context-induced reinstatement of heroin seeking. J Neurosci 2012; 32(14): 4982-4991. 15. Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry 2011; 16(10): 974-986.
Supplementary 11. Top diseases and bio functions annotations derived from Ingenuity Pathway Analysis (IPA) Group Category P value Number of molecules Diseases and disorders Neurological disease 1.61E-02 – 1.13E-17 140 Psychological disorders 8.90E-03 – 7.12E-06 69 Hereditary disorder 1.51E-02 – 2.22E-05 51 Organismal injury and abnormalities 1.61E-02 – 2.22E-05 358 Skeletal and muscular disorders 1.60E-02 – 2.22E-05 88 Molecular and cellular functions Cell cycle 1.57E-02 – 1.59E-05 60 Cellular compromise 1.61E-02 – 1.59E-05 19 Cellular development 1.51E-02 – 4.04E-05 163 Cellular growth and proliferation 1.51E-02 – 4.87E-05 175 Lipid metabolism 1.59E-02 – 1.07E-04 22 Physiological system development and function Behavior 1.50E-02 – 1.57E-07 57 Nervous system development and function 1.61E-02 – 1.57E-07 108 Connective tissue development and function 1.23E-02 – 5.52E-07 69 Skeletal and muscular system development and function 1.61E-02 – 5.52E-07 73 Tissue morphology 1.50E-02 – 5.52E-07 112
Drd2 1.05 ± 0.23 0.83 ± 0.17# Htr1a 1.08 ± 0.36 0.50 ± 0.21** Htr2a 1.15 ± 0.17 0.97 ± 0.14# Grin1 1.07 ± 0.18 0.79 ± 0.33 Cnr1 0.85 ± 0.07 1.10 ± 0.14** Gria1 0.91 ± 0.13 0.96 ± 0.11 Fabp Fabp3 1.42 ± 0.59 1.22 ± 0.20 Fabp5 0.95 ± 0.60 1.29 ± 0.53 Fabp7 0.88 ± 0.85 1.60 ± 0.61# Others Comt 1.10 ± 0.12 0.83 ± 0.28* Maoa 1.05 ± 0.18 1.01 ± 0.09 Th 1.35 ± 0.39 0.63 ± 0.24*** Mecp2 0.90 ± 0.34 0.42 ± 0.19* Igf2 1.06 ± 0.36 0.69 ± 0.23* Nes 0.74 ± 0.28 0.65 ± 0.17 Bdnf 1.38 ± 0.71 1.07 ± 0.30 Values are mean ± SD. #P < 0.1, *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001, unpaired t test. Blue font, lower than the AA(+)/DHA(+) group; Red font, higher than the AA(+)/DHA(+) group.
Supplementary Table 16. Analysis of the ontology for genes that were annotated in ‘transcription of DNA’ Pathway Number of hit molecules Number of molecules P value Nuclear receptor transcription pathway 19 53 3.99E - 16 Genetic transcription pathway 27 141 9.45E – 15 Circadian clock 15 39 1.68E – 13 Cytokine signaling in immune system 32 270 2.71E – 11 BMAL1: CLOCK/NPAS2 activats circadian expression 9 15 8.93E – 11 The gene-ontology analysis for the genes annotated in ‘transcription of DNA’ was performed using Network Analyst (http://www.networkanalyst.ca/).
Supplementary Table 17. Analysis of gene expression by qPCR in 6 month-old C57BL/6 mice (prefrontal cortex) for the two diet groups Category Gene name AA(+)/DHA(+) AA(-)/DHA(-) Transcriptional factor 0.84 ± 0.34 0.26 ± 0.17** Pparb/d 0.90 ± 0.13 0.69 ± 0.19# Pparg 0.67 ± 0.47 0.97 ± 0.30 Rxra 1.00 ± 0.23 0.61 ± 0.09** Rxrb 0.93 ± 0.29 0.60 ± 0.16* Rxrg 0.81 ± 0.09 0.93 ± 0.09# Rara 0.66 ± 0.10 0.86 ± 0.17* Rarb 1.05 ± 0.12 1.02 ± 0.16 Rarg 0.82 ± 0.16 0.49 ± 0.32# Srebf1 1.04 ± 0.36 0.59 ± 0.12* Srebf2 0.88 ± 0.10 0.83 ± 0.05 Values are mean ± SD. #P < 0.1, *P < 0.05, **P < 0.01, unpaired t test. Blue font, than the AA(+)/DHA(+) group; Red font, higher than the AA(+)/DHA(+) group.
PPARalpha:RXRalpha -888 (+) ctgGGTACcaagggtgacc RXR, LXR, PXR, CAR, RAR, COUP -952 (-) cTGACCt PPARgamma -952 (-) cTGACCt FXR:RXR -958 (+) tggttgcTGACCtg Mal NM_010762 PPARgamma:RXR-alpha -169 (+) tagagtcAAAGGaca PPARgamma:RXRalpha -171 (+) catagAGTCAaaggacacggg RXRalpha -308 (-) aaaaAGAAA RXRalpha -353 (+) TTCCCtttc RXRalpha -354 (+) TTTCCcttt RXR-ALPHA secondary motif -407 (+) tggggTAGGTggaggt PPARgamma:RXR-alpha -737 (+) tgagggaATAGGgga Mobp NM_001039365 RXR:RAR -158 (-) tagccttttgtTAAACt RXRalpha -215 (+) TTTCTtttt RXR-ALPHA secondary motif -338 (+) gcctgTAGGTtgtggt RXR-ALPHA secondary motif -565 (+) gcataTAGTTtatgca PPARalpha:RXRalpha -884 (+) aagccataggcCATAGgttt GABA Gad1 NM_008077 RXR-ALPHA secondary motif -456 (-) gagaaaACCTTctgga